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Noninvasive Imaging of Plaque Inﬂammation
Role of Contrast-Enhanced MRI*
William S. Kerwin, PHD
Seattle, WashingtonIn recent years, great strides have been made in
noninvasive imaging of atherosclerotic plaque, mo-
tivated by the potential to identify specific plaque
characteristics associated with clinical sequelae or
disease progression. In this endeavor, inflammation
has been a prominent imaging target because of its
importance in all stages of plaque development.
Intimal infiltration of inflammatory cells is one of
See page 1127
the first steps in the development of an atheroscle-
rotic lesion (1). Development of a necrotic core is
driven by apoptosis of macrophage-derived foam
cells and the entry of blood cells through leaky
neovessels stimulated by proinflammatory media-
tors (2). Disruption of the overlying fibrous cap
leads to clinical thromboembolic events and may be
precipitated by degradation of the fibrous matrix via
matrix metalloproteinases released from inflamma-
tory cells (3). Thus, imaging plaque inflammation
may play a role in diagnosing high-risk plaque,
identifying therapeutic targets, or evaluating novel
anti-inflammatory therapies.
Within the atherosclerosis imaging community,
inflammation largely has been synonymous with
macrophages. It is important to recognize, however,
that inflammation is a multifaceted entity charac-
terized not only by macrophage infiltration, but also
by the presence of other immune cells, stimulation
of neovasculature, the presence of edema, and
changes in temperature and pH. All of these aspects
present opportunities for imaging inflammation.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Department of Radiology, University of Washington, and
VPDiagnostics, Inc., Seattle, Washington. Dr. Kerwin reports that he has
no relationships to disclose.In the case of neovasculature and edema, mag-
netic resonance imaging (MRI) with clinically used
gadolinium contrast agents can be remarkably pow-
erful. The entry and retention of these contrast
agents within atherosclerotic plaques is determined
by the extent and permeability of the neovascula-
ture. The resulting variations in contrast agent
uptake and patterns of enhancement are analogous
to the results of delayed enhancement and perfusion
MRI of the myocardium, which have become
powerful tools in the detection of fibrosis and
ischemia in the heart (4).
In this issue of iJACC, Hur et al. (5) explore the
use of contrast-enhanced MRI in a rabbit model of
atherosclerosis. They report a correlation between
vessel wall enhancement and density of neovessels
within the plaque. This corroborates previous re-
ports of a link between enhancement and neovessels
in a similar rabbit model (6) of atherosclerosis and
in human atherosclerotic disease (7,8).
Hur et al. (5) also demonstrate the relevance of
this finding to inflammation by demonstrating
strong relationships of both contrast enhancement
and neovessel density with macrophage content.
Again, this finding is supported in the prior litera-
ture on contrast-enhanced plaque MRI. In our own
work, we have used dynamic contrast-enhanced
MRI and kinetic modeling to probe plaque physi-
ology quantitatively in terms of fractional plasma
volume and contrast agent transfer constant (8–10).
These efforts have demonstrated correlations be-
tween these parameters and a variety of markers of
inflammation, including macrophages, neovessels,
and serum C-reactive protein.
A drawback of the study of Hur et al. (5) is that
their use of enhancement ratio to measure uptake is
affected by a variety of imaging and physiological
parameters, such as the volume of contrast agent
relative to the total volume of blood plasma or the
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1137mount of signal void resulting from calcification.
utside the highly controlled rabbit model, the im-
act of physiological variability in a diverse human
opulation is uncertain. Nevertheless, this study is
mportant in further establishing the link between
ontrast agent uptake and plaque inflammation.
One point that distinguishes the work of Hur et
l. (5) from past studies is that the lesions studied in
he rabbit model are quite small in comparison with
he advanced carotid artery lesions evaluated in
rior human studies. Thin walls with small plaque
eposits present a technical challenge for many of
he past approaches to measuring enhancement,
hich are sensitive to partial volume effects from
he large contrast agent concentration in the vessel
umen. Hur et al. (5) address this problem with a
ovel 3-dimensional (3D) black-blood acquisition
hat effectively suppresses the lumen signal. The use of
D imaging also boosts the signal-to-noise ratio
ompared with 2-dimensional imaging techniques,
llowing high-resolution imaging. Thus, this result
erves as evidence of the feasibility and validity of
ontrast-enhanced MRI for the assessment of inflam-
ation in small or early lesions of atherosclerosis.
echnical advancement leading to robust 3D imaging
ith efficient blood suppression is an ongoing devel-
pment goal in vessel-wall MRI (11).
Although these findings emphasize the role that
ontrast-enhanced MRI can play in assessing
laque inflammation, the approach must be placed
nto context with the many other assessment tools
or plaque inflammation. Atherosclerosis has been
ne of the predominant targets in the emerging
eld of molecular imaging. Targeted contrast
gents for atherosclerosis have been proposed for
RI, positron emission tomography (PET), com-
uted tomography, and ultrasound imaging (12–
5). Molecular targets of the contrast agents have
ncluded numerous inflammatory markers, such as
3 integrin, matrix metalloproteinases, and the
acrophage scavenger receptor B (16–18). These
gents likely represent a bright future for imaging of
laque inflammation, but they face a long road
efore they are considered safe and effective for
arge-scale human use.
In the nearer term, imaging of plaque inflamma-
ion in humans will require the adaptation of
xisting technologies, such as contrast-enhanced
RI. Because inflammatory components, such as
acrophages, account for small fractions of the
otal plaque volume and exhibit no exogenous
ontrast, imaging of plaque inflammation requires
he use of injected agents. In addition to iadolinium-based MRI agents, studies have suc-
essfully linked inflammation to uptake of [18F]-
uorodeoxyglucose (FDG) in PET, ultrasmall su-
erparamagnetic iron oxides (USPIOs) in MRI,
nd microbubbles in ultrasound (19–21).
Each of these agents works on different, but
nterrelated, aspects of inflammation. For instance,
DG PET uses the fact that macrophages are the
redominant metabolically active cell in atheroscle-
otic plaque to identify inflamed regions with high
ctivity on subsequent PET images. USPIOs have
een shown to be ingested by macrophages residing
ithin atherosclerotic plaque, yielding signal voids
n MRI approximately 24 h after administration.
icrobubble contrast-enhanced ultrasound is most
nalogous to contrast-enhanced MRI, relying on
ree distribution of the agent into the plaque via
eovasculature. Nevertheless, given the importance
f the neovasculature in delivery of FDG or
SPIOs into the plaque, all of these strategies for
maging of plaque inflammation are likely to elicit
losely interdependent measurements.
In deciding among these approaches, a strong
ase can be made for contrast-enhanced MRI. First,
he absence of ionizing radiation makes MRI ideal
or serial research studies. Also, despite the risk of
ephrogenic systemic fibrosis in populations with
mpaired kidney function, gadolinium contrast
gents have an excellent safety profile. From a
ractical standpoint, contrast-enhanced MRI can
e performed in a single session lasting only min-
tes, whereas USPIOs require 2 imaging sessions
eparated by 24 h or more. Also, MRI is already
eading the field for comprehensive plaque analysis
n large arteries, such as the carotid (22). Therefore,
ontrast-enhanced MRI can be a minor add-on to
n existing MRI examination. In fact, the use of
adolinium contrast agents for MRI of atheroscle-
osis is already advocated for accurate detection of
laque components (23). Finally, MRI permits
igh-resolution imaging of plaque, with pixel di-
ensions of 500 m. This permits localized
easurements of enhancement, limited, for exam-
le, to fibrous regions of the plaque (24). With
egard to disadvantages of contrast-enhanced MRI,
n important distinction is the nonspecific nature of
ontrast agent uptake. Enhancement does not di-
ectly measure macrophages or other inflammatory
ells, but signifies an increase in plaque perfusion
hat is strongly associated with inflammatory cells.
Ultimately, imaging of inflammation in athero-
clerosis is intended as a clinical tool for identifying
ndividual plaques at risk of rupture. For this
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1138urpose, studies are needed that prospectively link
maging assessments of plaque inflammation to
utcomes. Another application where inflammation
maging is already in use is the evaluation of drug
herapies in clinical trials. Already, reports of statin
ffects on FDG uptake have been reported using
ET (25). Similar studies are under way using
ontrast-enhanced MRI.
Overall, contrast-enhanced MRI is a strong con-al. MR imaging of adventitial vasa can be detected bylaque inflammation. The next challenge is to
etermine to what extent it adds value to either
linical risk assessment or evaluation of therapeutic
ffects.
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